Intellia Therapeutics, Inc
NTLA
Key stats
- Open
- 11.00
- Day high
- 11.06
- Day low
- 10.46
- Previous close
- 11.41
- Volume
- 4.00M
- VWAP
- 10.69
- 52-week high
- 18.48
- 52-week low
- 7.95
- Market cap
- 1.60B
- Shares out
- 140.36M
- Employees
- 377
- Listed
- 2016
About Intellia Therapeutics, Inc
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · CAMBRIDGE, MA · intelliatx.com
Options · expiring Nov 20
Nov 12, 4:00 PM ET- Call open interest
- 3.5K
- Put open interest
- 3.4K
- Put/call
- 0.97
- At-the-money IV
- 90.9%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 9 call | 1.91 | Nov 12, 11:00 AM | 225 | 226 | 124.4% |
| 10 put | 0.30 | Nov 12, 3:52 PM | 187 | 669 | 101.0% |
| 12 call | 0.15 | Nov 12, 3:35 PM | 147 | 974 | 86.7% |
| 13 call | 0.06 | Nov 12, 3:36 PM | 138 | 1.7K | 107.4% |
| 11 call | 0.35 | Nov 12, 3:35 PM | 124 | 416 | 90.9% |
| 11 put | 0.76 | Nov 12, 3:00 PM | 17 | 1.0K | 92.3% |
Quarterly results
Massive · Nov 5, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $7.16M | $7.66M | $15.05M | $23.02M |
| Gross profit | $7.16M | $7.66M | $15.05M | $23.02M |
| Operating income | −$122.33M | −$112.76M | −$100.53M | −$98.71M |
| Net income | −$127.48M | −$106.63M | −$96.23M | −$95.79M |
| Diluted EPS | -0.91 | -0.80 | -0.81 | -0.83 |
| Operating cash flow | −$85.43M | −$83.11M | −$117.35M | −$69.28M |
| Assets | $902.56M | $857.16M | $758.78M | $842.13M |
| Liabilities | $289.47M | $129.46M | $137.84M | $170.73M |
| Equity | $613.09M | $727.71M | $620.94M | $671.39M |
Technicals
Massive · Nov 12, 2026- 50-day average11.98
- 200-day average12.98
- RSI (14 days)41.0
Short interest
Massive · Oct 30, 2026- Oct 30, 202644.36M shares · 11.1 days to cover
- Oct 15, 202644.44M shares · 6.5 days to cover
- Sep 30, 202645.11M shares · 9.5 days to cover
- Sep 15, 202646.68M shares · 14.1 days to cover
Related companies
MassiveNews coverage
No stories about Intellia Therapeutics, Inc right now.